On 16 April 2015, the GPhA launched its Biosimilars Council. The council, which will begin operations immediately, will comprise manufacturers and stakeholders working to ensure a positive regulatory, reimbursement, political and policy environment that supports patient access to biosimilars.

The council is also the industry’s first educational resource for the general public and patient groups seeking information about the safety and effectiveness of biosimilars, according to the GPhA. The council has already produced an educational handbook (The Next Frontier for Improved Access to Medicines: Biosimilars and Interchangeable Biologic Products), which explains the benefits and science behind biosimilar medicines, as safe, effective alternatives to costly brand-name biologicals.

The Biosimilars Council ‘is designed to meet the unique needs of healthcare companies as they navigate this emerging space’, according to Mr Craig Wheeler, GPhA Board Chairman and President and CEO of Momenta Pharmaceuticals.

GPhA also intends the Biosimilars Council ‘to be a key resource for organizations seeking relationship building opportunities, and a forum for in-depth scientific, regulatory, legislative and policy discussions’.

Related articles
Biosimilars Forum launched

More US state legislation on biosimilars substitution

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.